Page last updated: 2024-12-06

oleandomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Oleandomycin is a macrolide antibiotic produced by the bacterium *Streptomyces antibioticus*. It was first isolated in 1952 and was initially used to treat a variety of bacterial infections. Oleandomycin acts by inhibiting protein synthesis in bacteria, specifically by binding to the 50S ribosomal subunit and interfering with the translocation step of translation. It is effective against a wide range of gram-positive bacteria, including *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Streptococcus pyogenes*. However, its use has declined due to the emergence of antibiotic resistance and the availability of more effective alternatives. Research on oleandomycin has focused on understanding its mechanism of action, developing new derivatives with improved pharmacological properties, and exploring its potential therapeutic applications beyond bacterial infections. For example, some studies have suggested that oleandomycin may possess anti-inflammatory and anti-cancer activities. '

Cross-References

ID SourceID
PubMed CID72493
CHEMBL ID606258
CHEBI ID16869
SCHEMBL ID3717
MeSH IDM0015246

Synonyms (41)

Synonym
CHEBI:16869 ,
(3r,5r,6s,7r,8r,11r,12s,13r,14s,15s)-6-hydroxy-5,7,8,11,13,15-hexamethyl-4,10-dioxo-14-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-1,9-dioxaspiro[2.13]hexadec-12-yl 2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranoside
antibiotic pa-105
hsdb 7442
oleandomycine [inn-french]
einecs 223-495-7
oleandomycine [french]
oleandomycin (chloroform solvate)
12-((2,6-didesoxy-3-o-methyl-alpha-k-arabino-hexopyranosyl)oxy)-8-hydroxy-5,7,8,11,13,15-hexamethyl-14-((3,4,6-tridesoxy-3-dimethylamino-beta-d-xylo-hexopyranosyl)oxy)-1,9-dioxaspiro(2.13)hexadecan-4,10-dion
oleandomycinum [inn-latin]
oleandomicina [inn-spanish]
ai3-50163
NCGC00179617-01
PRESTWICK3_000152
BPBIO1_000314
BSPBIO_000284
AB00513809
romicil
C01946
amimycin
LMPK04000007
e704
CHEMBL606258
oleandomicina
oleandomycine
oleandomycinum
oleandomycin [inn]
oleandomycin [inn:ban]
unii-p8zq646136
p8zq646136 ,
SCHEMBL3717
oleandomycin [mi]
oleandomycin [hsdb]
oleandomycin [who-dd]
oleandomycin [green book]
RZPAKFUAFGMUPI-QESOVKLGSA-N
bdbm234401
DB11442
CS-0063452
HY-116010
oleandomycin 1000 microg/ml in acetonitrile
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oleandomycins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 2B7Homo sapiens (human)IC50 (µMol)154.00000.10002.50004.9000AID1802994
UDP-glucuronosyltransferase 1-6Homo sapiens (human)IC50 (µMol)154.00004.90004.90004.9000AID1802994
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)154.00000.30003.25807.3000AID1802994
UDP-glucuronosyltransferase 1A4Homo sapiens (human)IC50 (µMol)154.00004.72004.81004.9000AID1802994
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)IC50 (µMol)154.00004.90004.90004.9000AID1802994
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1-6Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1-6Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
UDP-glycosyltransferase activityUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1-6Homo sapiens (human)
intracellular membrane-bounded organelleUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B10 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay IDTitleYearJournalArticle
AID510747Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID279898Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279879Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID19403Calculated partition coefficient (logD)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279904Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID23096The negative logarithm of the fraction of neutral molecules1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279864Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID510559Antibacterial activity against Escherichia coli AG102MB2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID279884Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279905Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID503238Activity of Streptomyces antibioticus OleD A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID279878Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID23733Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279870Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID503236Activity of Streptomyces antibioticus OleD P67T mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID510750Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID24865The negative logarithm of the fraction of singly charged molecules.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279890Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID503239Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID279901Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID279899Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279889Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID279886Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279875Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279876Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279869Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID503237Activity of Streptomyces antibioticus OleD S123F mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID519669Inhibition of PAR2-mediated SLIGKV-NH2-induced interleukin-8 production in normal human epidermal keratinocytes preincubated for 24 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.
AID279863Antimicrobial activity against Burkholderia pseudomallei KHW2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279887Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID510749Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID279877Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279868Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID503235Activity at Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID279872Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID117681Protective dose at which 50% of infected, treated mice survive1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279902Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279883Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279888Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID19425HPLC capacity factor (k)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279865Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279900Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279881Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279880Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279866Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID21658Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279867Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279874Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID26629Dissociation constant (pKa)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279882Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID155915Minimum inhibitory concentration against Pasteurella multocida.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID510748Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID279897Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279885Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279903Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279873Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID419498Volume of distribution at steady state in human2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID19662Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID279871Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802994UDP-glucuronosyltransferase Activity Assay from Article 10.3109/14756366.2010.518965: \\The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.\\2011Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 26, Issue:3
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's5 (50.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.29 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index48.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]